Form D · Pharmaceuticals
XTL BIOPHARMACEUTICALS LTD
Raanana, L3 · CIK 0001023549
Offering snapshot reported Mar 29, 2017 · SEC filing
- Reported sold
- $2.8M Offering amount: $2.8M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 15, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 29, 2017 | Initial | $2,800,000 | No comparison | 22 | SEC filing |
| Mar 1, 2017 | Initial | $2,500,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-283590
The offering includes an aggregate of 1,400,000 unregistered ADSs and unregistered warrants to purchase 1,400,000 ADSs.
Source: Form D, filed Mar 29, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Bassa | Director |
| Ossi Hillel Fain | Director |
| David Kestenbaum | Executive |
| Joshua Levine | Executive |
| Dobroslav Melamed | Director |
| Oded Nagar | Director |
| Jonathan Schapiro | Director |
| Shlomo Shalev | Director |
| Doron Turgeman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 Hacharoshet St.
Raanana, L3, 4365603
Raanana, L3, 4365603